Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma's HLP003 program in major depressive disorder and expand outreach in veteran communities. HLP003, a proprietary novel serotonergic agonist (NSA), is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc. founded in 2019, is committed to helping minds heal through its proprietary NSAs. In addition to HLP003, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder, and has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The correction underscores the importance of accurate communication in clinical-stage pharmaceutical partnerships, particularly those involving veteran communities and government initiatives. The collaboration with TARA Mind aligns with a recent executive order focused on expanding mental health treatments and clinical research participation, highlighting the broader implications for advancing mental health care.
For more information about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The full press release is available at https://ibn.fm/re8HL.
